Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | FPR2 | P25090 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | FPR3 | P25089 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330154 | 0.93 | FPR2 (0.47) | GPR119FPR2KDM4EPKMFPR3 | |
| SCHEMBL23329477 | 0.88 | USP30 (0.46) | GPR119FPR2FPR3ALDH1A1 | |
| SCHEMBL4248138 | 0.88 | KDM4E (0.60) | GPR119KDM4EPKMMAPTTHRB | |
| SCHEMBL23329642 | 0.87 | ALDH1A1 (0.59) | GPR119KDM4EPKMALDH1A1 | |
| SCHEMBL17394099 | 0.86 | FPR2 (0.50) | GPR119FPR2FPR3ALDH1A1MAPT | |
| SCHEMBL25572016 | 0.86 | TGFBR1 (0.52) | GPR119KDM4EPKMMAPTTHRB | |
| SCHEMBL796552 | 0.84 | KDM4E (0.57) | GPR119KDM4EPKMTHRB | |
| SCHEMBL385082 | 0.83 | ALDH1A1 (0.46) | GPR119PKMALDH1A1 | |
| SCHEMBL23329870 | 0.83 | USP30 (0.50) | GPR119FPR2KDM4EPKMFPR3 | |
| SCHEMBL5440270 | 0.82 | GPR119 (0.54) | GPR119FPR2KDM4EFPR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | Modern Biosciences Limited (GB) | 2024-12-10 | — | — | US | disclosed |
| CN-113766953-B | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses | 现代生物科学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| EP-3956030-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2022-02-23 | — | — | EP | disclosed |
| CN-113766953-A | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic use | 现代生物科学有限公司 | 2021-12-07 | — | — | CN | disclosed |
| WO-2021083209-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2021-05-06 | — | — | WO | disclosed |
| WO-2020212581-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212581-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-10-22 | — | — | WO | disclosed |
| EP-2964635-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | MCL1, BCL9, BCL9L | GPR119 629/4885FPR2 259/4885KDM4E 1383/4885 |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GPR119 1212/4885FPR2 3909/4885KDM4E 2720/4885 |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | MCL1, BCL9, BCL9L | GPR119 629/4885FPR2 259/4885KDM4E 1383/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | GPR119 2201/4885FPR2 4355/4885KDM4E 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.